KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Operating Leases (2019 - 2025)

Historic Operating Leases for West Pharmaceutical Services (WST) over the last 7 years, with Q4 2025 value amounting to $118.3 million.

  • West Pharmaceutical Services' Operating Leases rose 4462.1% to $118.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $118.3 million, marking a year-over-year increase of 4462.1%. This contributed to the annual value of $118.3 million for FY2025, which is 4462.1% up from last year.
  • According to the latest figures from Q4 2025, West Pharmaceutical Services' Operating Leases is $118.3 million, which was up 4462.1% from $94.9 million recorded in Q3 2025.
  • West Pharmaceutical Services' 5-year Operating Leases high stood at $118.3 million for Q4 2025, and its period low was $61.5 million during Q3 2021.
  • Its 5-year average for Operating Leases is $89.8 million, with a median of $94.0 million in 2022.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 1189.11% in 2021, then surged by 4761.9% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Operating Leases (Quarter) stood at $63.0 million in 2021, then surged by 47.62% to $93.0 million in 2022, then decreased by 9.14% to $84.5 million in 2023, then decreased by 3.2% to $81.8 million in 2024, then surged by 44.62% to $118.3 million in 2025.
  • Its Operating Leases stands at $118.3 million for Q4 2025, versus $94.9 million for Q3 2025 and $100.7 million for Q2 2025.